Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions

Jenna K. Kawamoto, PharmD, Jason P. Smith, PharmD, Steven-Huy B. Han, MD, AGAF


Direct-acting antiviral (DAA) protease inhibitors, boceprevir (BOC) and telaprevir (TVR) were FDA-approved in 2011 to be used in combination with pegylated interferon (peg-IFN) and ribavirin for the treatment of chronic hepatitis C virus infection (HCV) genotype 1. The addition of these new DAAs increased cure rates but also increased rates of adverse events and drug interactions. This review will evaluate HCV treatment-related side-effects, toxicity, and drug-interactions and management. Understanding and identifying adverse events and drug interactions will help enable the provider to minimize treatment discontinuation, prevent serious adverse events, and optimize treatment for patients.


Hepatitis C, protease inhibitors, boceprevir, telaprevir, adverse events, drug interactions

Full Text:



Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 (Suppl 1):74-81.

Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444.

Backus LI, Boothroyd DB, Phillips BR, et al, A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-516.

van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24):2584-2593.

Jacobson IM, McHutchison JG, Dusheiko G, et al., Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 2011. 364(25): 2405-2416.

Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med, 2011. 364(25): 2417-2428.

Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med, 2011. 364(13): 1207-1217.

Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13): 1195-1206.

Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013; 57(3):974-984.

Hezode C, Fontaine H, Dorival C, et al, Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434-441.

Fellay J, Thompson AJ, Ge D, et al., ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405-408.

Thompson AJ, Clark PJ, Singh A, et al., Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012;56(2):313-319.

Poordad F, Lawitz E, Reddy KR, et al. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology. 2013;145(5):1035-1044.

Sulkowski MS. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. Journal of Hepatology. 54(Suppl 1):S195.

Hammond KP, Jimmerson L, MacBrayne CE, et al. Increased Plasma and Intracellular Ribavirin Concentrations Associated With Telaprevir Use. Atlanta: 29th Conference on Retroviruses and Opportunistic Infections, 2013.

Pegasys (peginterferon alfa-2a) package insert, Hoffmann-La Roche Inc, Nutley, NJ, 2011.

Roomer R, Hansen BE, Janssen HL, de Kneqt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol, 2010. 53(3): 455-459.

Howell CD, Jeffers LS, Cassidy W, et al. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13(6):371-376.

Promacta (Eltrombopag) [package insert]. GlaxoSmithKline. Research Triangle Park, NC, 2012.

Afdhal N. Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated With Thrombocytopenia [abstract]. In: 62nd Annual Meeting of the American Association for the Study of Liver Disease; 2011. 4-8; San Francisco, California (CA): AASLD; 2011. Abstract LB-3.

Dusheiko G. Results of ENABLE 2, a Phase 3, Placebo-controlled, Multicenter Study of Eltrombopag, Peginterferon Alfa-2b, and Ribavirin Treatment in Patients with Hepatitis C and Thrombocytopenia [abstract]. In: 47th Annual European Association for the Study of Liver; 2012 April 20; Barcelona, Spaon: EASL; 2012. Abstract #279.

FDA Antiviral Drugs Advisory Committee. Telaprevir briefing document April 28, 2011., 2011. Accessed 10/5/2012.

Incivek (Telaprevir) [package insert], Vertex Inc.Cambridge MA. April 2013.

Victrelis (Boceprevir) [package insert], Merck Inc. February 2013.

Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54(1):20-27.

World Health Organization. Drospirenone-containing combined oral contraceptives: possible increased risk of blood clots. WHO Pharm Newslett. 2011;6:5.

Simeprevir [package insert]. Janssen-Cilag, SpA, Latina, Italy. Janssen Products, LP, 2013.

Sofosbuvir [package insert]. Foster City, CA: Gilead Sciences, Inc, 2013.


  • There are currently no refbacks.